U.S. childhood vaccination rates fall again as exemptions set another record
NEW YORK — U.S. kindergarten vaccination rates inched down again last year and the share of children with exemptions rose to an all-time high, according to federal data posted Thursday.
The fraction of kids exempted from vaccine requirements rose to 4.1 per cent, up from 3.7 per cent the year before. It's the third record-breaking year in a row for the exemption rate, and the vast majority are parents withholding shots for nonmedical reasons.
Meanwhile, 92.5 per cent of 2024-25 kindergartners got their required measles-mumps-rubella shots, down slightly from the previous year. Before the COVID-19 pandemic, the vaccination rate was 95 per cent — the level that makes it unlikely that a single infection will spark a disease cluster or outbreak.
The vaccination numbers were posted as the U.S. experiences its worst year for measles spread in more than three decades, with more than 1,300 cases so far.
The U.S. Centers for Disease Control and Prevention (CDC) traditionally releases the vaccination coverage data in its flagship publication, the Morbidity and Mortality Weekly Report. CDC officials usually speak to the trends and possible explanations, and stress the importance of vaccinations. This year, the agency quietly posted the data online and — when asked about it — emailed a statement.
'The decision to vaccinate is a personal one. Parents should consult their health care providers on options for their families,' the statement said, adding; 'Vaccination remains the most effective way to protect children from serious diseases like measles and whooping cough, which can lead to hospitalization and long-term health complications.'
Public health officials focus on vaccination rates for kindergartners because schools can be cauldrons for germs and launching pads for community outbreaks.
For years, those rates were high, thanks largely to school attendance mandates that required key vaccinations. All U.S. states and territories require that children attending child care centers and schools be vaccinated against a number of diseases, including, measles, mumps, polio, tetanus, whooping cough and chickenpox.
All states allow exemptions for children with medical conditions that prevent them from receiving certain vaccines. And most also permit exemptions for religious or other nonmedical reasons.
In the last decade, the percentage of kindergartners with medical exemptions has held steady, at about 0.2 per cent. But the percentage with nonmedical exemptions has risen.
The rates can be influenced by policies that make it harder or easier to obtain exemptions, and by local attitudes among families and doctors about the need to get children vaccinated. Online misinformation and the political divide that emerged around COVID-19 vaccines have led more parents to question routine childhood vaccinations, experts say.
According to the CDC data, 15.4 per cent of kindergartners had an exemption to one or more vaccines in Idaho in the last school year. But fewer than 0.5 per cent did in Connecticut.
___
Mike Stobbe, The Associated Press
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
2 hours ago
- Winnipeg Free Press
Americans get more than half their calories from ultraprocessed foods, CDC report says
Most Americans get more than half their calories from ultraprocessed foods, those super-tasty, energy-dense foods typically full of sugar, salt and unhealthy fats, according to a new federal report. Nutrition research has shown for years that ultraprocessed foods make up a big chunk of the U.S. diet, especially for kids and teens. For the first time, however, the U.S. Centers for Disease Control and Prevention has confirmed those high levels of consumption, using dietary data collected from August 2021 to August 2023. The report comes amid growing scrutiny of such foods by Health Secretary Robert F. Kennedy Jr., who blames them for causing chronic disease. 'We are poisoning ourselves and it's coming principally from these ultraprocessed foods,' Kennedy told Fox News earlier this year. Overall, about 55% of total calories consumed by Americans age 1 and older came from ultraprocessed foods during that period, according to the report. For adults, ultraprocessed foods made up about 53% of total calories consumed, but for kids through age 18, it was nearly 62%. The top sources included burgers and sandwiches, sweet baked goods, savory snacks, pizza and sweetened drinks. Young children consumed fewer calories from ultraprocessed foods than older kids, the report found. Adults 60 and older consumed fewer calories from those sources than younger adults. Low-income adults consumed more ultraprocessed foods than those with higher incomes. The results were not surprising, said co-author Anne Williams, a CDC nutrition expert. What was surprising was that consumption of ultraprocessed foods appeared to dip slightly over the past decade. Among adults, total calories from those sources fell from about 56% in 2013-2014 and from nearly 66% for kids in 2017-2018. Williams said she couldn't speculate about the reason for the decline or whether consumption of less processed foods increased. But Andrea Deierlein, a nutrition expert at New York University who was not involved in the research, suggested that there may be greater awareness of the potential harms of ultraprocessed foods. 'People are trying, at least in some populations, to decrease their intakes of these foods,' she said. Concern over ultraprocessed foods' health effects has been growing for years, but finding solutions has been difficult. Many studies have linked them to obesity, diabetes and heart disease, but they haven't been able to prove that the foods directly cause those chronic health problems. One small but influential study found that even when diets were matched for calories, sugar, fat, fiber and micronutrients, people consumed more calories and gained more weight when they ate ultraprocessed foods than when they ate minimally processed foods. Research published this week in the journal Nature found that participants in a clinical trial lost twice as much weight when they ate minimally processed foods — such as pasta, chicken, fruits and vegetables — than ultraprocessed foods, even those matched for nutrition components and considered healthy, such as ready-to-heat frozen meals, protein bars and shakes. Part of the problem is simply defining ultraprocessed foods. The new CDC report used the most common definition based on the four-tier Nova system developed by Brazilian researchers that classifies foods according to the amount of processing they undergo. Such foods tend to be 'hyperpalatable, energy-dense, low in dietary fiber and contain little or no whole foods, while having high amounts of salt, sweeteners and unhealthy fats,' the CDC report said. Wednesdays What's next in arts, life and pop culture. U.S. health officials recently said there are concerns over whether current definitions 'accurately capture' the range of foods that may affect health. The U.S. Food and Drug Administration and the Agriculture Department recently issued a request for information to develop a new, uniform definition of ultraprocessed foods for products in the U.S. food supply. In the meantime, Americans should try to reduce ultraprocessed foods in their daily diets, Deierlein said. For instance, instead of instant oatmeal that may contain added sugar, sodium, artificial colors and preservatives, use plain oats sweetened with honey or maple syrup. Read food packages and nutrition information, she suggested. 'I do think that there are less-processed options available for many foods,' she said. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Globe and Mail
4 hours ago
- Globe and Mail
Pulmatrix (PULM) Q2 Revenue Falls 100%
Key Points GAAP revenue dropped to zero in Q2 2025, with no new product sales or clinical trial sponsorships. Net loss per share (GAAP) was $(0.42) in Q2 2025, reflecting significant spending cuts and a substantial reduction in R&D activity. Pulmatrix focused on finalizing its merger with Cullgen and pursuing asset divestitures; no forward financial guidance was provided. These 10 stocks could mint the next wave of millionaires › Pulmatrix (NASDAQ:PULM), a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025. Net loss per share (GAAP) was $(0.42), compared to $(1.59) in Q2 2024. There were no Wall Street analyst estimates available this quarter, but the reported GAAP loss per share of $(0.42) represented a substantial narrowing from last year's GAAP result of $(1.59) in Q2 2024, mainly due to a near-total reduction in research and development spending. The quarter highlights Pulmatrix's strategic pivot: winding down its prior clinical business, trimming operational costs, conserving cash, and focusing on completing its merger with Cullgen. The company offered no forward guidance for upcoming quarters as it transitions operations. Business Overview and Recent Areas of Focus Pulmatrix's core business has centered on developing inhaled therapies using its proprietary iSPERSE™ technology—a dry powder drug delivery platform aimed at improving medication delivery to the lungs. This platform was designed to increase efficiency and tolerability in treatments compared to traditional inhalers or oral medications, positioning the company in the respiratory therapeutics space. Over the past year, Pulmatrix's strategic priorities have shifted dramatically. It has halted most clinical operations, halted R&D spending, and now seeks to divest its iSPERSE™ intellectual property and remaining clinical assets. The company's ongoing viability depends on successfully completing its pending merger with Cullgen and monetizing its assets or securing royalty streams from former drug candidates such as PUR1900. Key success factors now rest less on product development and more on the execution of these strategic transactions. Quarter Highlights: Operations, Finances, and Pipeline Progress The quarter reflected a sharp operational downsizing as Pulmatrix's GAAP revenue dropped from $1.6 million in Q2 2024 to zero. This change resulted from the completion of the wind-down of its PUR1900 clinical trial. Former sources of operating income, such as milestone payments or funding for joint studies, concluded, and there were no new business or sales streams to replace them during the period. Research and development expense (GAAP) decreased from $2,834,000 in Q2 2024 to $14,000, a 99.5% drop. This near-total reduction in research spending came as Pulmatrix finished closing its flagship clinical programs and terminated related staff. The company stated: 'The decrease was primarily due to winding down the PUR1900 Phase 2b clinical trial, disposal of the Company's lab and facilities lease and employee terminations.' Helped by layoffs and cuts, although these savings were partially offset by legal and advisory expenses linked to the merger process. Net loss and operating loss (GAAP) both narrowed substantially. The reduced losses were primarily due to a sharp decrease in R&D expenses. Net loss (GAAP) dropped to $(1.55) million from $(5.81) million in Q2 2024. The company avoided any unusual charges this quarter, whereas the prior period had included a significant loss from an asset transaction with MannKind. With its extreme cost containment, Pulmatrix exited the quarter with a GAAP cash and cash equivalents position of $5.8 million (down from $9.5 million at December 31, 2024), which management expects will fund operations until the Cullgen merger is finalized. This period also saw Pulmatrix focus on two main strategic moves apart from operational cuts: the attempted sale of its iSPERSE™ intellectual property and clinical programs, and its merger with Cullgen. The company openly stated, 'Pulmatrix is currently in a process to potentially divest its patent portfolio for our iSPERSE™ technology, as well as three related clinical programs.' These pipeline programs include PUR3100 for acute migraine (an orally inhaled dihydroergotamine engineered with iSPERSE™), PUR1800 for chronic obstructive pulmonary disease (a kinase inhibitor also using the iSPERSE™ platform), and PUR1900 (an inhaled formulation of an antifungal, developed with Cipla). Development or commercial responsibility for these candidates has ended or shifted to partners, and Pulmatrix itself has no ongoing clinical trials. Regulatory milestones from past years continued to carry some legacy value. For example, the Food and Drug Administration had accepted a Phase 2 study for PUR3100 and Pulmatrix's partner Cipla is moving forward with Phase 3 for PUR1900 in India. Pulmatrix may be eligible to receive a 2% royalty on possible future non-U.S. sales of PUR1900, but this would only occur if the product is successfully commercialized—a long-term and uncertain proposition. The most critical development during the second quarter was continued progress toward completing the merger with Cullgen, a protein degrader drug development company. Pulmatrix received stockholder approval and had its registration statement declared effective by the Securities and Exchange Commission. The merger remains contingent on regulatory approvals, including from the China Security Regulatory Commission and Nasdaq. Until the deal closes, Pulmatrix is in a holding pattern, and the company highlights that any delay or failure in closing poses significant risks to its ongoing viability. Looking Ahead: Guidance and Watchpoints Pulmatrix did not provide any financial guidance or operational outlook for the next quarter or upcoming year. No revenue or earnings forecast was offered by management in the latest earnings release. The company's leadership made clear that the near-term objective is to complete the planned merger and monetize or transfer its remaining assets. Because Pulmatrix is not currently developing or selling any medications, its short-term future is heavily dependent on successful asset divestitures and getting the Cullgen deal across the finish line. Investors and observers should monitor progress toward merger closing, potential updates on the sale of iSPERSE™-related patent portfolios, and any royalty developments with former pipeline candidates. PULM does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
CBC
4 hours ago
- CBC
RFK Jr.'s move to axe $500M in vaccine funding slammed
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has announced a $500-million cut to funding for mRNA vaccine development, insisting the technology used in COVID-19 vaccines poses risks. Many medical experts say the reasoning is untrue and could slow development of future vaccinations.
